Doctors track Real-World results of Vision-Saving eye injections
NCT ID NCT04543331
Summary
This study observed how well an eye injection called brolucizumab worked in everyday medical practice for patients with two common causes of vision loss: 'wet' age-related macular degeneration (AMD) and diabetic macular edema (DME). It followed 572 patients in Germany for up to two years to see how the treatment reduced fluid in the retina and affected vision. The goal was to understand how the drug performs outside of strict clinical trials, using only data from routine doctor visits.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Würzburg, Bavaria, 97070, Germany
-
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Göttingen, Lower Saxony, 37075, Germany
-
Novartis Investigative Site
Osnabrück, Lower Saxony, 49076, Germany
-
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, 18057, Germany
-
Novartis Investigative Site
Trier, Rhineland-Palatinate, 54296, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
Schneeberg, Saxony, 08289, Germany
-
Novartis Investigative Site
Halle, Saxony-Anhalt, 06118, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Aschersleben, 06449, Germany
-
Novartis Investigative Site
Bayreuth, 95445, Germany
-
Novartis Investigative Site
Berlin, 10713, Germany
-
Novartis Investigative Site
Berlin, 14163, Germany
-
Novartis Investigative Site
Bonn, 53105, Germany
-
Novartis Investigative Site
Breisach, 79206, Germany
-
Novartis Investigative Site
Chemnitz, 09113, Germany
-
Novartis Investigative Site
Cologne, 50968, Germany
-
Novartis Investigative Site
Dresden, 01067, Germany
-
Novartis Investigative Site
Dresden, 01324, Germany
-
Novartis Investigative Site
Esslingen am Neckar, 73728, Germany
-
Novartis Investigative Site
Glauchau, 08371, Germany
-
Novartis Investigative Site
Homburg, 66421, Germany
-
Novartis Investigative Site
Hösbach, 63768, Germany
-
Novartis Investigative Site
Kiel, 24103, Germany
-
Novartis Investigative Site
Leipzig, 04106, Germany
-
Novartis Investigative Site
Magdeburg, 39104, Germany
-
Novartis Investigative Site
Marienberg, 09496, Germany
-
Novartis Investigative Site
Münster, 48145, Germany
-
Novartis Investigative Site
Neubrandenburg, 17036, Germany
-
Novartis Investigative Site
Neuburg am Inn, 86633, Germany
-
Novartis Investigative Site
Saarbrücken, 66111, Germany
-
Novartis Investigative Site
Schönebeck, 39218, Germany
-
Novartis Investigative Site
Stralsund, 18435, Germany
-
Novartis Investigative Site
Sulzbach, 66280, Germany
-
Novartis Investigative Site
Torgau, 04860, Germany
-
Novartis Investigative Site
Waren, 17192, Germany
-
Novartis Investigative Site
Würzburg, 97080, Germany
Conditions
Explore the condition pages connected to this study.